Expression and distribution of AAV9 and a novel AAV2 variant following intrathecal and sub-pial administration in African green monkeys
This poster details the comparative analysis of biodistribution and neuronal transduction efficiencies of AAV9 and the novel AAV2 mutant when delivered via lumbar intrathecal, cisterna magna, and sub-pial methods.
Using green fluorescent protein (GFP) as a marker, the study highlights how different administration routes impact gene expression levels and neuronal infection patterns, providing essential insights for optimizing gene delivery strategies.
This research is crucial for developers looking to maximize the therapeutic potential of gene therapies, as it guides the refinement of vector delivery techniques to achieve more effective and widespread transduction.
At Virscio, we utilize the outcomes of this study to advance the field of gene therapy by developing more precise and efficient vector delivery methods. Our research supports the continuous improvement of therapeutic strategies, helping to overcome existing limitations in gene therapy applications. By providing a deeper understanding of vector distribution patterns and transduction efficiencies, we enable our partners to design better-targeted therapies that can more effectively treat a range of CNS disorders.
In this scientific poster, you will learn more about:
- Advanced insights into CNS-targeted gene therapy vector distribution
- Comparative effects of intrathecal and sub-pial administrations on neuronal transduction
- Innovations in AAV vector design to enhance biodistribution and infectivity
- Implications for the development of more effective gene therapy treatments
Ready to Deepen Your Understanding?
Download Our Scientific Poster Now!
Ready to Deepen Your Understanding? Download Our Scientific Poster Now!
Explore normal clinical pathology and physiology reference ranges for African green monkeys (AGM) compared to cynomolgus macaques.